Male/female | 9 (30%)/21 (70%) |
Age (years) | 51 (41.75 to 62) |
Disease duration (years) | 3 (1 to 6) |
Anti-DNA topoisomerase I/anti-centromere antibodies | 28 (93.3%)/1 (3.3%) |
Systemic sclerosis, lcSSc/dcSSc | 14 (46%)/16 (53.3%) |
Pulmonary function tests | |
FVC% predicted | 76.5 (63.23 to 89.30) |
TLC% predicted | 75 (65 to 86) |
DLco% predicted | 43 (37 to 54) |
High-resolution computed tomography | |
Ground-glass | 10 (6 to 13.75) |
Honeycombing | 10.5 (6.25 to 16.25) |
Modified Rodnan skin score | 10.5 (5.25 to 20) |
Health Assessment Questionnaire | 0.375 (0 to 1) |